Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 7/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461121 | 1.00 | SLC6A9 (0.44) | SLC6A9SSTR1SSTR4PGRDPP4 | |
| SCHEMBL5461125 | 1.00 | SLC6A9 (0.44) | SLC6A9SSTR1SSTR4PGRDPP4 | |
| SCHEMBL5456237 | 0.87 | SLC6A9 (0.40) | SLC6A9SSTR1SSTR4PGRDPP4 | |
| SCHEMBL5456238 | 0.87 | SLC6A9 (0.40) | SLC6A9SSTR1SSTR4PGRDPP4 | |
| Hydrochloric Acid SCHEMBL5463007 | 0.86 | SLC6A9 (0.40) | SLC6A9SSTR1SSTR4PGRDPP4 | |
| Hydrochloric Acid SCHEMBL5463006 | 0.86 | SLC6A9 (0.40) | SLC6A9SSTR1SSTR4PGRDPP4 | |
| SCHEMBL5456219 | 0.79 | TAS1R3 (0.47) | SLC6A9MDM2 | |
| SCHEMBL14564676 | 0.78 | GAA (0.48) | SLC6A9CNR1 | |
| SCHEMBL14564672 | 0.76 | TRPV1 (0.42) | SLC6A9CNR1 | |
| SCHEMBL5457722 | 0.70 | SLC6A9 (0.49) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-03-22 | — | — | US | claimed |
| EP-1718609-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-11-08 | — | — | EP | claimed |
| WO-2005077897-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | claimed |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | US | claimed |
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-03-22 | — | — | US | disclosed |
| EP-1718609-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005077897-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | SLC6A9 1388/4885SSTR1 1464/4885SSTR4 946/4885 |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | SLC6A9 1388/4885SSTR1 1464/4885SSTR4 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.